Short answer
Taysha Gene Therapies, Inc. (TSHA) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$33M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- −100.0% YoY · −100.0% QoQ
- Net income
- −$33M
- −28.2% YoY · −21.8% QoQ
- EPS (diluted)
- −$0.09
- +10.0% YoY · +0.0% QoQ
Source: XBRL data from the Taysha Gene Therapies, Inc. (TSHA) Q3 2025 10-Q on SEC EDGAR. USD.
Taysha Gene Therapies, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New legal risk: SEC subpoenas in late 2024 investigating August 2023 PIPE and public offerings
- Materially updated clinical risk: May 2025 Phase 1/2 REVEAL TSHA-102 data preliminary, may materially change as more patient data accrue
- Legal risk: Consolidated stockholder derivative lawsuits since Jan/Apr 2024 seeking damages, special litigation committee investigation ongoing
- Operational risk: Limited experience conducting pivotal trials and regulatory filings may delay TSHA-102 approval and commercialization
- Financial risk: No material changes disclosed; dependence on successful regulatory approval and commercialization of sole product candidate TSHA-102
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Taysha Gene Therapies, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.